124 related articles for article (PubMed ID: 38086167)
1. m6A-modified RIPK4 facilitates proliferation and cisplatin resistance in epithelial ovarian cancer.
Yin X; Zhao S; Zhang M; Xing J; Zhou J; Gao W; Chen L; Zhang Y; Lin L; Lu M; Li W; Shang J; Zhu X
Gynecol Oncol; 2024 Jan; 180():99-110. PubMed ID: 38086167
[TBL] [Abstract][Full Text] [Related]
2. ALKBH5-HOXA10 loop-mediated JAK2 m6A demethylation and cisplatin resistance in epithelial ovarian cancer.
Nie S; Zhang L; Liu J; Wan Y; Jiang Y; Yang J; Sun R; Ma X; Sun G; Meng H; Xu M; Cheng W
J Exp Clin Cancer Res; 2021 Sep; 40(1):284. PubMed ID: 34496932
[TBL] [Abstract][Full Text] [Related]
3. ALKBH5 activates FAK signaling through m6A demethylation in
Sun R; Yuan L; Jiang Y; Wan Y; Ma X; Yang J; Sun G; Zhou S; Wang H; Qiu J; Zhang L; Cheng W
Theranostics; 2023; 13(2):833-848. PubMed ID: 36632222
[No Abstract] [Full Text] [Related]
4. Sulforaphene suppressed cell proliferation and promoted apoptosis of COV362 cells in endometrioid ovarian cancer.
Yu HY; Yang L; Liu YC; Yu AJ
PeerJ; 2023; 11():e16308. PubMed ID: 38025760
[TBL] [Abstract][Full Text] [Related]
5. Circulating exosomal circFoxp1 confers cisplatin resistance in epithelial ovarian cancer cells.
Luo Y; Gui R
J Gynecol Oncol; 2020 Sep; 31(5):e75. PubMed ID: 32808501
[TBL] [Abstract][Full Text] [Related]
6. miR-874-3p mitigates cisplatin resistance through modulating NF-κB/inhibitor of apoptosis protein signaling pathway in epithelial ovarian cancer cells.
Wang Y; Yan C; Qi J; Liu C; Yu J; Wang H
Mol Cell Biochem; 2022 Jan; 477(1):307-317. PubMed ID: 34716858
[TBL] [Abstract][Full Text] [Related]
7. FSTL1 increases cisplatin sensitivity in epithelial ovarian cancer cells by inhibition of NF-κB pathway.
Liu YK; Jia YJ; Liu SH; Ma J
Cancer Chemother Pharmacol; 2021 Mar; 87(3):405-414. PubMed ID: 33392640
[TBL] [Abstract][Full Text] [Related]
8. METTL3-mediated m6A modification of lnc RNA RHPN1-AS1 enhances cisplatin resistance in ovarian cancer by activating PI3K/AKT pathway.
Cui S
J Clin Lab Anal; 2022 Dec; 36(12):e24761. PubMed ID: 36336887
[TBL] [Abstract][Full Text] [Related]
9. Long noncoding RNA ZEB1-AS1 affects paclitaxel and cisplatin resistance by regulating MMP19 in epithelial ovarian cancer cells.
Dai C; Xu P; Liu S; Xu S; Xu J; Fu Z; Cao J; Lv M; Zhou J; Liu G; Zhang H; Jia X
Arch Gynecol Obstet; 2021 May; 303(5):1271-1281. PubMed ID: 33151424
[TBL] [Abstract][Full Text] [Related]
10. METTL3 regulates m6A in endometrioid epithelial ovarian cancer independently of METTl14 and WTAP.
Ma Z; Li Q; Liu P; Dong W; Zuo Y
Cell Biol Int; 2020 Dec; 44(12):2524-2531. PubMed ID: 32869897
[TBL] [Abstract][Full Text] [Related]
11. The m6A Methyltransferase METTL3-Mediated N6-Methyladenosine Modification of DEK mRNA to Promote Gastric Cancer Cell Growth and Metastasis.
Zhang HM; Qi FF; Wang J; Duan YY; Zhao LL; Wang YD; Zhang TC; Liao XH
Int J Mol Sci; 2022 Jun; 23(12):. PubMed ID: 35742899
[TBL] [Abstract][Full Text] [Related]
12. HNRNPA2B1-mediated m6A modification of FOXM1 promotes drug resistance and inhibits ferroptosis in endometrial cancer via regulation of LCN2.
Jiang J; Zhu J; Qiu P; Ni J; Zhu W; Wang X
Funct Integr Genomics; 2023 Dec; 24(1):3. PubMed ID: 38091112
[TBL] [Abstract][Full Text] [Related]
13. ZSWIM4 inhibition improves chemosensitivity in epithelial ovarian cancer cells by suppressing intracellular glycine biosynthesis.
Gong K; Huang Y; Zheng Y; Hao W; Shi K
J Transl Med; 2024 Feb; 22(1):192. PubMed ID: 38383406
[TBL] [Abstract][Full Text] [Related]
14. N6-methyladenosine-modified circPLPP4 sustains cisplatin resistance in ovarian cancer cells via PIK3R1 upregulation.
Li H; Lin R; Zhang Y; Zhu Y; Huang S; Lan J; Lu N; Xie C; He S; Zhang W
Mol Cancer; 2024 Jan; 23(1):5. PubMed ID: 38184597
[TBL] [Abstract][Full Text] [Related]
15. The N6-methyladenosine modification enhances ferroptosis resistance through inhibiting SLC7A11 mRNA deadenylation in hepatoblastoma.
Liu L; He J; Sun G; Huang N; Bian Z; Xu C; Zhang Y; Cui Z; Xu W; Sun F; Zhuang C; Man Q; Gu S
Clin Transl Med; 2022 May; 12(5):e778. PubMed ID: 35522946
[TBL] [Abstract][Full Text] [Related]
16. METTL16 Inhibits the Malignant Progression of Epithelial Ovarian Cancer through the lncRNA MALAT1/
Li C; Liu J; Lyu Y; Ling S; Luo Y
Anal Cell Pathol (Amst); 2023; 2023():9952234. PubMed ID: 37927399
[TBL] [Abstract][Full Text] [Related]
17. Tumor-associated macrophages promote cisplatin resistance in ovarian cancer cells by enhancing WTAP-mediated N6-methyladenosine RNA methylation via the CXCL16/CXCR6 axis.
Hong L; Wang X; Zheng L; Wang S; Zhu G
Cancer Chemother Pharmacol; 2023 Jul; 92(1):71-81. PubMed ID: 37272931
[TBL] [Abstract][Full Text] [Related]
18. Methyltransferase-like 3 enhances cell proliferation and cisplatin resistance in natural killer/T-cell lymphoma through promoting N6-methyladenosine modification and the stability of staphylococcal nuclease and Tudor domain-containing protein 1 mRNA.
Li N; Wei J; Zhang Q; Zhang Q; Liu B
Anticancer Drugs; 2023 Jun; 34(5):627-639. PubMed ID: 36730541
[TBL] [Abstract][Full Text] [Related]
19. Long non-coding RNA GAS5 inhibits DDP-resistance and tumor progression of epithelial ovarian cancer via GAS5-E2F4-PARP1-MAPK axis.
Long X; Song K; Hu H; Tian Q; Wang W; Dong Q; Yin X; Di W
J Exp Clin Cancer Res; 2019 Aug; 38(1):345. PubMed ID: 31391118
[TBL] [Abstract][Full Text] [Related]
20. Methylation recognition protein YTH N6-methyladenosine RNA binding protein 1 (YTHDF1) regulates the proliferation, migration and invasion of osteosarcoma by regulating m6A level of CCR4-NOT transcription complex subunit 7 (CNOT7).
Wei K; Gao Y; Wang B; Qu YX
Bioengineered; 2022 Mar; 13(3):5236-5250. PubMed ID: 35156522
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
